文献速递肝病消化道肿瘤与早癌

慢性乙肝患者血清HBV DNA中等水平与最高肝癌风险相关

Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients.
PubMed 文献 · Aliment Pharmacol Ther · 2020-04-14

韩国一项历史性队列研究纳入6949例无肝硬化、未治疗且ALT持续正常超过1年的慢性乙肝患者,随访8.0年发现363例(5.2%)发生肝癌。多因素Cox回归显示基线HBV DNA 6-7 log10 IU/mL者肝癌风险最高(aHR 4.98),而>8 log10 IU/mL者风险最低(aHR 0.90),该关联独立于其他预测因素且在各年龄亚组一致。

要点

  • 基线HBV DNA 6-7 log10 IU/mL的慢性乙肝患者肝癌风险最高(aHR 4.98)。
  • HBV DNA>8 log10 IU/mL者肝癌风险并未升高(aHR 0.90)。
  • 该关联在各年龄亚组(<40、40-49、≥50岁)中一致。

核心结论

  • 在无显著ALT升高的慢性乙肝患者中,基线血清HBV DNA 6-7 log10 IU/mL者肝癌风险最高。
  • 可考虑将治疗指征扩展至HBV DNA中等水平的慢性乙肝患者以进一步预防肝癌,无论ALT水平如何。

研究设计与样本

  • 韩国历史性队列研究,纳入6949例无肝硬化、未治疗且ALT<2倍正常上限持续>1年的慢性乙肝患者。
  • 基线HBV DNA>6 log10 IU/mL者2029例(29.2%),随访至启动抗病毒治疗时删失。
  • 中位随访8.0年,平均年龄45岁。

主要发现

  • 随访期间363例(5.2%)发生肝癌。
  • 多因素Cox回归显示,基线HBV DNA 6-7 log10 IU/mL者肝癌风险最高(aHR 4.98;P<0.001)。
  • 基线HBV DNA>8 log10 IU/mL者肝癌风险最低(aHR 0.90;P=0.71),≤4 log10 IU/mL为参照(aHR 1.00)。
  • HBV DNA水平与肝癌风险的关联独立于其他预测因素,并在各年龄亚组(<40、40-49、≥50岁)中一致。

关键数值与推荐

  • 基线HBV DNA 6-7 log10 IU/mL:aHR 4.98(P<0.001)。
  • 基线HBV DNA>8 log10 IU/mL:aHR 0.90(P=0.71)。
  • 基线HBV DNA≤4 log10 IU/mL:参照组,aHR 1.00。

临床怎么用

  • 对无显著ALT升高但HBV DNA处于6-7 log10 IU/mL的慢性乙肝患者,应警惕最高肝癌风险。
  • 可考虑对此类中等HBV DNA水平患者扩展抗病毒治疗指征以预防肝癌, regardless of ALT levels。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Studies have shown a higher risk of hepatocellular carcinoma (HCC) with higher baseline serum hepatitis B virus (HBV) DNA levels in chronic hepatitis B (CHB) patients. However, the association between very high HBV DNA levels (>6 log10 IU/mL) and HCC risk remains unclear, especially in middle-aged and old HBeAg-positive patients. AIM: To identify the association between broad-range HBV DNA levels and HCC risk. METHODS: We conducted a historical cohort study in Korea involving 6949 non-cirrhotic, treatment-naïve CHB patients with alanine aminotransferase (ALT) <2× upper limit of normal for >1 year. HBV DNA was >6 log10 IU/mL in 2029 (29.2%) patients. Follow-up was censored when the antiviral therapy was initiated. RESULTS: The mean age of the patients was 45 years. During 8.0 years of median follow-up, 363 patients (5.2%) developed HCC. By multivariable Cox regression analysis, HCC risk was highest with baseline HBV DNA levels of 6-7 log10 IU/mL (adjusted hazard ratio [aHR] 4.98; P < 0.001), and lowest with >8 log10 IU/mL (aHR 0.90; P = 0.71) and ≤4 log10 IU/mL (aHR 1.00; reference), which was independent of other predictive factors. The similar association between HBV DNA levels and HCC risk was consistently observed in all age subgroups (age <40, 40-49 and ≥ 50 years). CONCLUSIONS: HCC risk was highest with moderate serum HBV DNA levels of 6-7 log10 IU/mL in CHB patients without significant ALT elevation. Extending treatment indication to CHB patients with moderate levels of HBV DNA may be considered to further prevent HCC, regardless of ALT levels.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kim GA, Han S, Choi GH, et al. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients. Aliment Pharmacol Ther. 2020. PMID: 32291781. doi:10.1111/apt.15725

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。